Skip to main content
SpringerLink
Log in

So far, so good for sofosbuvir at ISPOR

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. financed by Gilead

  2. financed by Gilead

  3. financed by Gilead

  4. financed by Gilead

  5. financed by Gilead

  6. financed by Gilead

  7. Japanese yen

References

  1. De Groote K, et al. The Costs-Effectiveness of Sofosbuvir Versus Standard of Care (Soc) in Chronic Hepatitis C from a Belgian Reimbursement Perspective. 17th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes : (plus poster) abstr. PGI48, 8 Nov 2014. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=37939.

  2. Cortesi PA, et al. The Cost-Effectiveness of Sofosbuvir and Ribavirin Treatment in Hcv-Infected Patients Listed for Liver Transplantation. 17th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes : abstr. PGI29, 8 Nov 2014. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=37892.

  3. Silva M, et al. Sofosbuvir for the Treatment of Chronic Hepatitis C: a Comprehensive Cost-Effectiveness Analysis Across Hcv Genotypes, Pretreatment Conditions and Hiv Co-Infection. 17th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes : abstr. PGI23, 8 Nov 2014. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=38064.

  4. Cure S, et al. Cost-Effectiveness and Long-Term Outcomes of Sovaldi (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infected (Hcv) Patients from a Swedish Societal Perspective. 17th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes : (plus poster) abstr. PIN67, 8 Nov 2014. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=39506.

  5. Novak A, et al. The Pan-Genotypic Costs-Effectiveness of Sofosbuvir in Hepatitis C Virus. 17th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes : (plus poster) abstr. PIN73, 8 Nov 2014. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=39462.

  6. Novak A, et al. Costs Per Successfully Treated Patient with Sofosbuvir in Gt1 Hcv. 17th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes : (plus poster) abstr. PIN55, 8 Nov 2014. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=39463.

  7. Igarashi A, et al. Cost-Utility Analysis of Sofosbuvir for Treatment of Genotype2 Chronic Hepatitis C in Japan. 17th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes : abstr. PGI30, 8 Nov 2014. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=37790.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

So far, so good for sofosbuvir at ISPOR. PharmacoEcon Outcomes News 717, 35–36 (2014). https://doi.org/10.1007/s40274-014-1760-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1760-8

Search

Navigation